share_log

bluebird bio | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(5.40%)

bluebird bio | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(5.40%)

bluebird bio | SC 13G/A:超过5%持股股东披露文件(修正)-The Vanguard Group(5.40%)
美股SEC公告 ·  2024/11/13 08:17

Moomoo AI 已提取核心信息

The Vanguard Group has filed an amended Schedule 13G/A with the Securities and Exchange Commission on November 13, 2024, indicating a change in their holdings of bluebird bio, Inc. common stock. As of September 30, 2024, The Vanguard Group reported beneficial ownership of 10,474,007 shares of bluebird bio, which represents 5.40% of the company's class of common stock. The filing shows that The Vanguard Group has shared voting power over 87,543 shares and sole dispositive power over 10,330,825 shares, with an additional shared dispositive power over 143,182 shares. The Vanguard Group, a Pennsylvania-based investment adviser, stated that the securities were not acquired for the purpose of changing or influencing the control of bluebird bio, Inc. and were not held in connection with any transaction having that purpose or effect.
The Vanguard Group has filed an amended Schedule 13G/A with the Securities and Exchange Commission on November 13, 2024, indicating a change in their holdings of bluebird bio, Inc. common stock. As of September 30, 2024, The Vanguard Group reported beneficial ownership of 10,474,007 shares of bluebird bio, which represents 5.40% of the company's class of common stock. The filing shows that The Vanguard Group has shared voting power over 87,543 shares and sole dispositive power over 10,330,825 shares, with an additional shared dispositive power over 143,182 shares. The Vanguard Group, a Pennsylvania-based investment adviser, stated that the securities were not acquired for the purpose of changing or influencing the control of bluebird bio, Inc. and were not held in connection with any transaction having that purpose or effect.
The Vanguard集团已于2024年11月13日向证券交易委员会提交了修订后的13G/A表,表明他们持有bluebird bio, Inc.普通股的持股变化。截至2024年9月30日,The Vanguard集团报告持有bluebird bio的10,474,007股普通股,这占了公司普通股类的5.40%。该申报显示The Vanguard集团共同持有87,543股表决权,并独立行使对10,330,825股的表决权,另外还通过共同持有对143,182股的表决权。总部位于宾夕法尼亚的投资顾问The Vanguard集团表示,这些证券并非出于改变或影响bluebird bio, Inc.控制权的目的而收购,并非在与具有此目的或影响的交易相关的情况下持有。
The Vanguard集团已于2024年11月13日向证券交易委员会提交了修订后的13G/A表,表明他们持有bluebird bio, Inc.普通股的持股变化。截至2024年9月30日,The Vanguard集团报告持有bluebird bio的10,474,007股普通股,这占了公司普通股类的5.40%。该申报显示The Vanguard集团共同持有87,543股表决权,并独立行使对10,330,825股的表决权,另外还通过共同持有对143,182股的表决权。总部位于宾夕法尼亚的投资顾问The Vanguard集团表示,这些证券并非出于改变或影响bluebird bio, Inc.控制权的目的而收购,并非在与具有此目的或影响的交易相关的情况下持有。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息